IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 25.1GRADE F
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
-13.6%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Century Therapeutics, Inc. (IPSC) receives a "Reduce" rating with a composite score of 39.2/100, ranked #2763 out of 4446 stocks. Key factor scores: Quality 25/100, Value 29/100, Momentum 79/100. This is quantitative analysis only — not investment advice.
Century Therapeutics, Inc. (IPSC) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Century Therapeutics, Inc. Do?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. Century Therapeutics, Inc. (IPSC) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Osvaldo Flores and employs approximately 170 people. With a market capitalization of $394M, IPSC is one of the notable companies in the Healthcare sector.
Century Therapeutics, Inc. (IPSC) Stock Rating — Reduce (April 2026)
As of April 2026, Century Therapeutics, Inc. receives a Reduce rating with a composite score of 39.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IPSC ranks #2,763 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Century Therapeutics, Inc. ranks #378 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
IPSC Stock Price and 52-Week Range
Century Therapeutics, Inc. (IPSC) currently trades at $2.25. The stock lost $0.01 (0.4%) in the most recent trading session. The 52-week high for IPSC is $3.04, which means the stock is currently trading -26.0% from its annual peak. The 52-week low is $0.34, putting the stock 558.3% above its annual trough. Recent trading volume was 911K shares, suggesting relatively thin trading activity.
Is IPSC Overvalued or Undervalued? — Valuation Analysis
Century Therapeutics, Inc. (IPSC) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.56x, versus the sector average of 2.75x. The price-to-sales ratio is 3.69x, compared to 1.66x for the average Healthcare stock.
At current multiples, Century Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Century Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score
Century Therapeutics, Inc. (IPSC) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -13.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -9.7% versus the sector average of -33.1%.
The operating margin is -2165.1% (sector: -66.1%). Net profit margin stands at -1938.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
IPSC Debt, Balance Sheet, and Financial Health
Century Therapeutics, Inc. has a debt-to-equity ratio of 41.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.97x, indicating strong short-term liquidity. Total debt on the balance sheet is $8M. Cash and equivalents stand at $56M.
IPSC has a beta of 1.32, meaning it is more volatile than the broader market — a $10,000 investment in IPSC would be expected to move 31.7% more than the S&P 500 on any given day. The stability factor score for Century Therapeutics, Inc. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Century Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Century Therapeutics, Inc. reported revenue of $110M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-22M. Operating income came in at $-31M.
In FY 2025, Century Therapeutics, Inc. reported revenue of $109M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-10M. Revenue grew 1556.8% year-over-year compared to FY 2024. Operating income came in at $-17M.
In Q3 2025, Century Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-34M. Operating income came in at $-36M.
In Q2 2025, Century Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.38. Net income for the quarter was $-33M. Operating income came in at $-35M.
Over the past 8 quarters, Century Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $771,000 to $110M. Investors analyzing IPSC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
IPSC Dividend Yield and Income Analysis
Century Therapeutics, Inc. (IPSC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
IPSC Momentum and Technical Analysis Profile
Century Therapeutics, Inc. (IPSC) has a momentum factor score of 79/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
IPSC vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing IPSC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IPSC vs S&P 500 (SPY) comparison to assess how Century Therapeutics, Inc. stacks up against the broader market across all factor dimensions.
IPSC Next Earnings Date
No upcoming earnings date has been announced for Century Therapeutics, Inc. (IPSC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy IPSC? — Investment Thesis Summary
The quantitative profile for Century Therapeutics, Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Price momentum is positive at 79/100, suggesting the trend favors buyers. High volatility (stability score 29/100) increases portfolio risk.
In summary, Century Therapeutics, Inc. (IPSC) earns a Reduce rating with a composite score of 39.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IPSC stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
Century Therapeutics, Inc. (IPSC) Deep Dive Analysis
Published on March 24, 2026
Action RatingReduce
Sections
Executive Summary
We maintain a Hold rating on Century Therapeutics (IPSC) with a composite score of 38.6/100, reflecting a balanced view of its potential and risks. The company's innovative approach to allogeneic cell therapies, particularly its iPSC-derived CAR-iNK and CAR-iT cell therapies, offers significant promise in treating solid tumors and hematological malignancies. However, the early stage of its pipeline, coupled with substantial cash burn and negative profitability metrics, tempers our enthusiasm, warranting a neutral stance until clinical trial data and financial performance demonstrate a clearer path to commercial success.
The most critical takeaway is the inherent uncertainty associated with early-stage biotechnology companies. While Century Therapeutics possesses a compelling technology platform and targets significant unmet medical needs, the path to regulatory approval and market adoption is fraught with challenges. Investors should closely monitor clinical trial outcomes, cash runway, and strategic partnerships to assess the company's ability to navigate the complexities of drug development and ultimately deliver value.
Business Strategy & Overview
Century Therapeutics operates as a biotechnology company focused on developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs). This approach aims to create off-the-shelf cell therapies that can be manufactured at scale and administered to multiple patients, overcoming the limitations of autologous cell therapies, which are patient-specific and costly to produce. The company's strategy centers on leveraging its iPSC platform to generate CAR-iNK and CAR-iT cell therapies targeting various cancers, including B-cell lymphomas, glioblastoma, acute myeloid leukemia, and multiple myeloma.
The company's lead product candidate, CNTY-101, targets CD19 for relapsed, refractory B-cell lymphoma and is currently in preclinical development. Other pipeline assets include CNTY-103 targeting CD133 + EGFR for recurrent glioblastoma, CNTY-102 targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies, CNTY-104 for acute myeloid leukemia, and CNTY-106 for multiple myeloma. These programs are also in the preclinical stage, reflecting the early stage of the company's overall development efforts.
Century Therapeutics' business model relies on advancing its pipeline through preclinical and clinical development, ultimately seeking regulatory approval and commercialization. This process is capital-intensive and requires significant investment in research and development, manufacturing capabilities, and clinical trials. The company may also pursue strategic partnerships with larger pharmaceutical companies to accelerate development and commercialization efforts, potentially through licensing agreements or co-development arrangements.
The competitive landscape for cell therapies is rapidly evolving, with numerous companies developing both autologous and allogeneic approaches. Key competitors include companies developing CAR-T cell therapies, such as Novartis and Gilead, as well as other companies focused on allogeneic cell therapies. Century Therapeutics differentiates itself through its iPSC-derived platform, which offers the potential for scalability and reduced manufacturing costs compared to other allogeneic approaches. However, the company faces significant challenges in demonstrating the safety and efficacy of its therapies in clinical trials and competing with established players in the field.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
-100.0%
Sector: 10.6%
-1040% VS SCTR
Economic Moat Analysis
Century Therapeutics' economic moat is currently considered to be None. While the company possesses innovative technology in the form of its iPSC-derived allogeneic cell therapy platform, this technology is still in its early stages of development and has not yet been validated in clinical trials. The biotechnology industry is characterized by intense competition and rapid technological advancements, making it difficult for any single company to establish a sustainable competitive advantage.
The company's potential moat could be built upon intangible assets, specifically patents and proprietary know-how related to its iPSC platform and cell therapy manufacturing processes. However, the strength and enforceability of these patents remain uncertain, and competitors may be able to develop alternative technologies that circumvent Century Therapeutics' intellectual property. Furthermore, the regulatory pathway for cell therapies is complex and evolving, which could create additional barriers to entry for new players but also increase the risk of regulatory setbacks for Century Therapeutics.
Network effects are unlikely to be a significant source of competitive advantage for Century Therapeutics, as the company's therapies are not directly dependent on the size or connectivity of a user base. Switching costs for patients are also relatively low, as patients may be willing to switch to alternative therapies if they offer improved efficacy or safety profiles. Cost advantages could potentially arise from the scalability of the company's iPSC platform, which could lead to lower manufacturing costs compared to autologous cell therapies. However, these cost advantages have not yet been demonstrated in practice and may be offset by the high costs of clinical development and regulatory compliance.
Efficient scale is not a primary driver of competitive advantage in the cell therapy industry, as the market is still relatively small and fragmented. While larger companies may have advantages in terms of manufacturing capacity and distribution networks, smaller companies can still compete effectively by focusing on niche indications or developing innovative technologies. Overall, Century Therapeutics' lack of a demonstrable economic moat reflects the early stage of its development and the highly competitive nature of the biotechnology industry. The company will need to generate positive clinical trial data, secure strong intellectual property protection, and establish a clear path to commercialization in order to build a sustainable competitive advantage.
Financial Health & Profitability
Century Therapeutics' financial health presents a mixed picture. The company's most recent TTM revenue stands at $109.16 million, primarily driven by a significant $109.16 million revenue in Q1 FY2025. However, this is followed by zero revenue in the subsequent two quarters, suggesting a non-recurring event or milestone payment. This revenue spike is an anomaly compared to prior years, where revenue was significantly lower ($6.59M in FY2024 and $2.23M in FY2023). The company's net income for the TTM period is $-9.58 million, a substantial improvement compared to the net losses of $-126.57 million in FY2024 and $-136.67 million in FY2023, again largely due to the Q1 FY2025 revenue.
Despite the improved net income, Century Therapeutics' EBITDA remains negative at $-17.27 million, and its free cash flow is significantly negative at $-126.21 million, indicating a high cash burn rate. This is a common characteristic of early-stage biotechnology companies that are heavily investing in research and development. The company's total cash position is $55.52 million, while its total debt is relatively low at $8.34 million. The current ratio is high at 5.97, suggesting strong short-term liquidity.
Compared to the healthcare sector, Century Therapeutics' profitability metrics are significantly worse. The company's P/E and EV/EBITDA ratios are not applicable due to negative earnings and EBITDA. Its ROE is -13.6%, which is better than the sector average of -42.5%, but still indicative of negative returns. The company's operating margin is -2,165.1%, and net margin is -1,938.8%, both significantly lower than the sector averages of -65.2% and -54.1%, respectively. The company's revenue growth is -100.0%, significantly underperforming the sector average of 10.7%, but this is skewed by the unusual revenue pattern in FY2025.
The quarterly financial history reveals a consistent pattern of negative net income and operating margins, except for Q1 FY2025. The company's cash burn rate is a significant concern, and it will need to raise additional capital to fund its operations and advance its pipeline. The company's ability to secure additional funding will depend on its ability to generate positive clinical trial data and attract investor interest. While the company's balance sheet is currently healthy, its high cash burn rate and negative profitability metrics raise concerns about its long-term financial sustainability.
Valuation Assessment
Valuing Century Therapeutics is challenging due to its early stage of development and lack of consistent profitability. Traditional valuation metrics such as P/E and EV/EBITDA are not applicable due to negative earnings and EBITDA. The company's negative free cash flow further complicates the valuation process. Given these limitations, a more appropriate valuation approach would involve a risk-adjusted net present value (NPV) analysis of its pipeline assets, considering the probability of success, potential market size, and competitive landscape for each program. However, without detailed clinical trial data and market forecasts, it is difficult to perform a reliable NPV analysis.
The company's market capitalization of $434.93 million reflects investor expectations for its pipeline assets and technology platform. However, this valuation is highly speculative and subject to significant uncertainty. The company's high momentum score of 78/100 suggests that investor sentiment is currently positive, potentially driven by recent clinical trial updates or strategic partnerships. However, this momentum could quickly reverse if the company experiences setbacks in its clinical development programs or fails to meet investor expectations.
Compared to its peers in the biotechnology industry, Century Therapeutics' valuation appears to be in line with other early-stage companies with promising technology platforms. However, the biotechnology industry is characterized by high valuations and significant volatility, making it difficult to assess whether the company is truly undervalued or overvalued. The company's low value score of 28/100 suggests that its valuation is not particularly attractive based on traditional value metrics.
Overall, Century Therapeutics' valuation is highly dependent on the success of its clinical development programs and its ability to secure additional funding. Given the inherent risks and uncertainties associated with early-stage biotechnology companies, it is difficult to justify a strong buy rating based on valuation alone. The current Hold rating reflects a balanced view of the company's potential and risks, acknowledging the speculative nature of its valuation.
Risk & Uncertainty
Century Therapeutics faces several significant risks and uncertainties. The most prominent risk is the inherent uncertainty associated with drug development. The company's pipeline is in the early stages of development, and there is no guarantee that its therapies will be safe and effective in clinical trials. Clinical trial failures are common in the biotechnology industry, and even successful therapies may face regulatory hurdles or commercialization challenges.
Competition is another significant risk. The cell therapy field is rapidly evolving, with numerous companies developing both autologous and allogeneic approaches. Century Therapeutics faces competition from established players with greater resources and more advanced clinical programs. The company's ability to differentiate itself and compete effectively will depend on the unique features of its iPSC-derived platform and the clinical performance of its therapies.
Financial risk is also a concern. Century Therapeutics is currently burning through cash at a high rate, and it will need to raise additional capital to fund its operations and advance its pipeline. The company's ability to secure additional funding will depend on its ability to generate positive clinical trial data and attract investor interest. Failure to secure additional funding could force the company to curtail its development programs or seek strategic alternatives.
Regulatory risk is also present. The regulatory pathway for cell therapies is complex and evolving, and the company may face delays or setbacks in its efforts to obtain regulatory approval for its therapies. Changes in regulatory requirements or policies could also impact the company's development programs and commercialization plans.
Bulls Say / Bears Say
The Bull Case
BULL VIEWCentury Therapeutics' iPSC-derived allogeneic cell therapy platform offers a scalable and cost-effective approach to treating cancer, potentially disrupting the autologous cell therapy market.
BULL VIEWPositive preclinical data and early clinical trial results could drive significant investor interest and a re-rating of the stock, reflecting the potential of its pipeline assets.
BULL VIEWStrategic partnerships with larger pharmaceutical companies could provide validation of the company's technology and accelerate the development and commercialization of its therapies.
The Bear Case
BEAR VIEWThe company's high cash burn rate and reliance on future funding raise concerns about its long-term financial sustainability, particularly if clinical trials are delayed or unsuccessful.
BEAR VIEWCompetition from established players in the cell therapy field and the risk of clinical trial failures could significantly impair the value of Century Therapeutics' pipeline assets.
BEAR VIEWThe complexity of the regulatory pathway for cell therapies and potential changes in regulatory requirements could delay or prevent the approval of the company's therapies.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score IPSC and 4,400+ other equities.
Century Therapeutics, Inc. exhibits a 21% valuation discount relative to institutional benchmarks. This represents a constructive entry window based on current multiples.
Return on Assets
Efficiency of asset utilization
-9.7%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
—
Sector: 71.5%
Operating Margin
Core business profitability
-2165.1%
Sector: -66.1%
Net Margin
Bottom-line profitability
-1938.8%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
